← All trials
NCT01259856
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2011
- Primary completion
- Jun 1, 2017
- Completion date
- Jun 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 168
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Icahn School of Medicine at Mount SinaiLead sponsor
- Myeloproliferative Disorders Research ConsoritumCollaborator
- Mayo ClinicStudy chair
- Queen's University, BelfastStudy chair
- Assistance Publique - Hôpitaux de ParisStudy chair
- National Cancer Institute (NCI)Collaborator
- RocheCollaborator
- Icahn School of Medicine at Mount SinaiStudy chair
- Icahn School of Medicine at Mount SinaiSponsor investigator
- University of LondonStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.